Kirin gets Japanese rights to Shire's Agrylin
Executive Summary
The pharmaceutical division of Kirin Brewery Co., which specializes in hematology therapies, has licensed Japanese rights from Shire Pharmaceuticals to develop, label, register, and sell its thrombocythemia treatment Agrylin (anagrelide hydrochloride).
Deal Industry
- Pharmaceuticals
Deal Status
- Final
Deal Type
-
Alliance
- R&D and Marketing (Licensing)
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Email Deal
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice